Highlights of weekly biotech stock moves

Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) gained $0.77 to $11.79 last week after the U.K.'s NICE issued a final appraisal determination backing use of once-weekly Bydureon exenatide to treat Type II diabetes in triple and dual therapy regimens. The FAD is in line with a preliminary appraisal issued last October. Bydureon uses drug delivery technology from Alkermes plc (NASDAQ:ALKS), which was up $1.48 to $18.16 last week.

Arena Pharmaceuticals Inc. (NASDAQ:ARNA) was up $0.03 to $1.65 last week after FDA accepted for review a resubmitted NDA for lorcaserin to treat obesity. The PDUFA date is June 27...